This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Kabbinavar F et al. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil/leucovorin with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60–65
Rankin C et al. (2004) Dose effect of imatinib in patients with metastatic GIST: Phase III Sarcoma Group Study S0033. Proc Am Soc Clin Oncol 22: 819
Acknowledgements
The synopsis was written by Minal Chande, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Charles Blanke receives research support from Novartis.
Glossary
- BCR-ABL
-
A tyrosine kinase arising from the product of reciprocal translocation of chromosomes 9 and 22
- KIT
-
The protein product of the c-KIT gene; GIST are characterized by c-KIT expression
Rights and permissions
About this article
Cite this article
Blanke, C. Low dose versus high dose imatinib for gastrointestinal stromal tumors. Nat Rev Gastroenterol Hepatol 2, 76–77 (2005). https://doi.org/10.1038/ncpgasthep0086
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0086